Hospital, San Antonio, TX. The eligibility requirements for this study were: (a) a willingness to participate; (b) definite or classical RA;8 (c) treatment with NSAIDs alone, or with NSAIDs plus gold or D-penicillamine (choice determined by patient's physician); (d) patients remained on the drug of interest for at least three months; (e) clear cut improvement or failure to improve on the described regimen (definition below).
In a previous study3 we observed substantial variability of clinical findings when patients improved only modestly (between 20 and 50%). In order to avoid this variability and the attendant uncertainty patients were chosen for this study if their articular index improved more than 55% (75% for those on NSAIDs alone) or if it failed to improve (<10% improvement or worsening). More stringent criteria were applied to those treated with NSAIDs alone to improve our chances of observing a reduction of rheumatoid factor if this were due to clinical improvement on NSAIDs. Thus although the clinical criteria for inclusion were not strictly comparable, the selection process intentionally minimised the likelihood of observing a serologic trend associated with clinical improvement on NSAIDs alone. We reasoned that if a trend were not observed despite this bias it would be even more credible than if identically stringent criteria were applied to the group on NSAIDs. All patients were 183 selected for study before performing the laboratory studies. In summary, the study groups 
Results

PATIENT DESCRIPTION
Clinical characteristics of the patient groups are presented in Table 1 . Therapeutic groups were comparable in number, ranging from 13 to 16 Improved (8) 56 (41-64) 15 4F, 4M 11-3 (6-17) Not improved (5) 53 (50-59) 8 (5-10)
11-4 (6-17) Gold 15 Improved (9) 54 (36-65) 6 (03-220)
6F, 3M In previous studies rheumatoid factor reduction has been associated with certain forms of therapy. One study11 observed an increase of IgM rheumatoid factor after cessation of NSAIDs for two weeks. After reinstitution of NSAIDs for six weeks a significant reduction of circulating IgM RF was noted. No objective measurement of disease activity was made in this study. In our study, even in the group of patients preselected on the basis of dramatic clinical improvement (81%), the reduction of both IgG and IgM RFs failed to achieve statistical significance. However, our patients were taking a variety of NSAIDs and this therapy was not routinely altered at the time of entry. The previous study11 employed a single agent and therapy was modified at the onset of the study. Differences of design probably account for the discrepancies between these two studies.
Patients treated with D-penicillamine have often,14 but not uniformly,' experienced significant reductions of circulating rheumatoid factor during therapy. Although most studies employing agglutination techniques have noted a reduction of rheumatoid factor with D-penicillamine therapy, reduction has not always been significant even in the face of significant clinical improvement'5 16 
